Special reportA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update
Section snippets
Natural History of Chronic Hepatitis B Virus Infection
The accurate and early diagnosis of chronic HBV infection is an important step in patient management. An understanding of the natural history of CHB is fundamental to the evaluation and management of CHB, playing a critical role in the assessment of patient status and in guiding decisions regarding candidacy for treatment and treatment end points. The natural course of HBV infection is a dynamic interplay of complex interactions involving the virus, the hepatocyte, and the host immune response,
Hepatitis B Virus DNA and Disease Progression
Large, long-term population-based studies of HBsAg-positive individuals have demonstrated a strong relationship between the risk of progression to cirrhosis, HCC, or both and ongoing HBV replication.12, 35, 36, 37 In both natural history and therapeutic studies, patients with cirrhosis who are seropositive for HBeAg, HBV DNA, or both have an approximately 4-fold higher risk of further disease progression to decompensation, HCC, and death than do patients who are HBeAg seronegative.15, 38, 39, 40
Risk Factors for Disease Progression
Viral and host factors have been shown to influence disease progression to cirrhosis or HCC.15 In large, long-term, natural history studies of HBsAg-positive individuals, viral and disease factors that were predictive of HCC included the presence of HBeAg (hazard ratio [HR], 4.2), HBV DNA levels >104 copies/mL (HR, 2.7), and HBV DNA levels >105 copies/mL (HR, 8.9–10.7).12 Host factors included male gender (HR, 3.0), advanced age (HR, 3.6–8.3), alcohol consumption (HR, 2.6), and cigarette
Candidates for Hepatitis B Virus Screening and Vaccination
During the last 2 years, the guidelines for the screening and vaccination of individuals with HBV infection have been revised by the Centers for Disease Control and Prevention (CDC).42, 43 All persons in high-risk groups for hepatitis B should be screened for serum HBsAg (Table 3).40, 42, 43 Testing for hepatitis B should be performed on any person with risk factors for acquiring HBV infection and in persons with elevated liver enzymes or evidence of active liver disease without an identified
Fibrosis Screening
After initial serologic testing and HBV DNA quantification, it might also helpful to establish the baseline liver histology before the initiation of therapy and to exclude other causes of liver disease. Liver biopsy is currently the gold standard for this assessment, but its use is limited because of its invasiveness, and it only samples a small portion of the liver; in addition, it has limited interobserver and intraobserver concordance. Although significant progress has been made during the
Candidates for Therapy
Although there is general agreement on the tests that should be ordered in the initial evaluation of patients with chronic HBV infection (Table 4), controversy remains regarding the identification of candidates for therapy and how to follow patients who are not initially considered for therapy, particularly HBeAg-positive patients with high HBV DNA levels and normal ALT levels.
Goals of Therapy
The goal of therapy for CHB is to eliminate or significantly suppress the replication of HBV and prevent the progression of liver disease to cirrhosis, with culmination in liver failure, or HCC, eventually leading to death or transplantation. Hence, the primary aim of treatment should be to reduce and maintain serum HBV DNA at the lowest possible levels (ie, achieve durable HBV DNA suppression). This, in turn, will promote the other aims of therapy, including histologic improvement and ALT
Hepatitis B Therapies
Currently, 7 drugs are available for the management of chronic HBV infection in the United States: interferon alfa-2b, lamivudine, adefovir, entecavir, peginterferon alfa-2a, telbivudine, and tenofovir. At present, the preferred first-line treatment choices are entecavir, peginterferon alfa-2a, and tenofovir because of their superior efficacy, tolerability, and favorable resistance profiles in HBeAg-positive (Table 5) and HBeAg-negative (Table 6) CHB over comparable drugs in pivotal clinical
Peginterferon alfa-2a
The efficacy of peginterferon alfa-2a has been demonstrated in a large phase III randomized study that compared peginterferon alfa-2a 180 μg/wk, lamivudine 100 mg/day, and both drugs in combination for 48 weeks in patients with HBeAg-positive CHB.63 At the end of treatment, therapy with peginterferon alfa-2a, with or without lamivudine, resulted in significantly greater rates of HBeAg seroconversion, HBV DNA undetectability, and ALT normalization, compared with treatment with lamivudine alone (
Hepatitis B e Antigen–Positive Patients
The recommendations for the treatment of HBeAg-positive patients are summarized in Table 7. The panel recommends an HBV DNA level of ≥20,000 IU/mL as a reasonable threshold for determining candidates for treatment, in combination with elevated ALT levels. HBeAg-positive patients who have HBV DNA levels of <20,000 IU/mL are atypical and are not recommended routinely for treatment because the majority of these individuals have inactive disease. However, because these individuals might be at risk
Monitoring Virologic Response and Management of Resistance to Oral Antiviral Therapy
Prolonged antiviral therapy with the oral nucleosides and nucleotides is associated with the development of antiviral resistance.146 The rate of resistance depends on a number of factors, including pretreatment HBV DNA levels, potency of the antiviral agent, prior exposure to oral nucleoside or nucleotide antiviral therapy, duration of treatment, and the degree of genetic barriers to resistance to the individual drug. The long-term rates of resistance are highest for lamivudine (65%–70% at 4–5
Patients With Cirrhosis
Before the advent of effective antiviral therapy, the 5-year survival rate was 84% for patients with compensated cirrhosis and 14%–35% for patients with decompensated cirrhosis.38, 155, 156 Various clinical parameters such as bilirubin level and older age were shown to predict survival. In addition, patients with compensated cirrhosis who lost HBeAg had 97% survival at 5 years, compared with 72% in HBeAg-positive patients; such findings implicated viral replication in adverse outcomes.38, 40,
Conclusion
For patients with chronic HBV infection, the primary goal of treatment is to prevent progression of liver disease to liver failure or HCC and prevent premature death or need for transplantation. On the basis of clinical and epidemiologic data, durable HBV DNA suppression is now considered the primary determinant of treatment outcomes, along with avoidance of resistance. The threshold level of HBV DNA for initiation of therapy remains unchanged at ≥20,000 IU/mL for patients with HBeAg-positive
References (196)
- et al.
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
Clin Gastroenterol Hepatol
(2004) - et al.
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
Clin Gastroenterol Hepatol
(2006) - et al.
Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B
Clin Gastroenterol Hepatol
(2007) - et al.
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
Gastroenterology
(2000) Host genetics and the outcome of hepatitis B viral infection
Transpl Immunol
(2005)- et al.
Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy
Gastroenterology
(1987) - et al.
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
Hepatology
(2002) - et al.
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection
Gastroenterology
(2002) - et al.
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
Gastroenterology
(2006) - et al.
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
Gastroenterology
(1992)
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients
Am J Gastroenterol
Long-term outcomes in hepatitis B: the REVEAL-HBV study
Clin Liver Dis
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study
Lancet
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
Lancet
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease
Hepatology
Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B
Gastroenterology
Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline
J Hepatol
Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan
Gastroenterology
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
Hepatology
Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F
Gastroenterology
Hepatitis B genotypes and the response to interferon therapy
J Hepatol
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
J Hepatol
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
Hepatology
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Gastroenterology
Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40 kD) ± lamivudine: 3-year follow-up results (abstract)
J Viral Hepat
Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?
Hepatology
The clinical significance of persistently normal ALT in chronic hepatitis B infection
J Hepatol
Management of hepatitis B: 2000—summary of a workshop
Gastroenterology
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
Hepatology
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
Gastroenterology
Hepatitis B virus infection
N Engl J Med
Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994
Am J Public Health
Prevalence of HBV and risk of HBV acquisition in hepatitis B screening programs in large metropolitan cities in the United States (abstract)
Hepatology
Screening for chronic hepatitis B among Asian/Pacific islander populations: New York City, 2005
MMWR Morb Mortal Wkly Rep
Chronic hepatitis B
Hepatology
EASL International Consensus Conference on Hepatitis B, 13-14 September, 2002 Geneva, Switzerland: consensus statement (long version)
J Hepatol
Chronic hepatitis B: treatment alert
Liver Int
Natural history and prognostic factors for chronic hepatitis type B
Gut
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
JAMA
Factors influencing liver disease progression in chronic hepatitis B
Liver Int
Natural history differences in perinatally versus adult acquired disease
Current Hepatitis Reports
Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005
Hepatology
Management of hepatitis B: summary of a clinical research workshop
Hepatology
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points
Ann Intern Med
Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase
Hepatology
Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus
Ann Intern Med
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
Ann Intern Med
The development of cirrhosis in patients with chronic type B hepatitis: a prospective study
Hepatology
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects
Hepatology
Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients
Hepatology
Cited by (423)
Utilization of Antiviral Therapy for Patients With Hepatitis B–Related Hepatocellular Carcinoma: A Nationwide Real-World US Study
2023, Clinical Gastroenterology and HepatologyTreatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update
2022, Clinical Gastroenterology and HepatologySubstantial gaps in evaluation and treatment of patients with hepatitis B in the US
2022, Journal of HepatologyInfluence of different delivery modes and HBV DNA titers on mother-to-child transmission of hepatitis B
2021, Clinics and Research in Hepatology and GastroenterologyPremature Rupture of Membranes with Concurrent Viral Infection
2020, Obstetrics and Gynecology Clinics of North America
The authors wish to thank Kathy Covino, PhD, for her editorial contributions and assistance in the preparation of the manuscript.
The authors disclose the following: This algorithm was developed with support by an unrestricted educational grant from Gilead Sciences.
Dr Keeffe is an employee of Romark Laboratories and has been a consultant for and served on advisory boards for Bristol-Myers Squibb, Gilead, Idenix, Novartis, and Roche. Dr Dieterich has received grant or research support and honoraria from Bristol-Myers Squibb, Gilead, Idenix, and Roche. Dr Han has received grant or research support, served on the advisory boards, and been a member of speakers' bureaus for Bristol-Myers Squibb, Gilead, and Roche. Dr Jacobson has received grant or research support from Coley, Gilead, Globelmmune, InterMune, Ribozyme, Valeant, and Schering-Plough; is a consultant for Anadys, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Coley, Gilead, Globelmmune, Idenix, InterMune, Novartis, Pfizer, Schering-Plough, Valeant, and Vertex; and is on speakers' bureaus for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Schering-Plough. Dr Martin has been a consultant, speaker, and investigator for Gilead, Bristol-Myers Squibb, Idenix, Novartis, Roche, and Schering. Dr Schiff has been a consultant to Abbott, Achillion, Bayer, Bristol-Myers Squibb, Cadence, Gilead, GlobeImmune, Idenix, Maxim, National Genetics Institute, Novartis, Ortho-Biotech, Pharmasset, Pfizer, PowerMed Limited, Prometheus, Roche Molecular, Salix, Sankyo Pharma, Schering-Plough, and SciClone; he has research grants and support including clinical trials from Abbott, Bayer, Bristol-Myers Squibb, Coley, Gilead, GlaxoSmithKline, Idenix, Ortho-Biotech, Prometheus, Roche Diagnostics, Roche Molecular, Roche Pharmaceutical, Schering-Plough, SciClone, and Vertex; and he has served on the speakers' bureau or received honoraria from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Ortho-Biotech, and Schering-Plough. Dr Tobias has served as a consultant and/or is on speakers' bureaus for Bristol-Myers Squibb, Gilead, Novartis and Roche.